MedPath

Evaluation of efficacy of Sufoof-e-Akseer-e-Jigar in Alcoholic Hepatitis.

Phase 2
Conditions
Health Condition 1: null- alcoholic hepatitis
Registration Number
CTRI/2014/11/005196
Lead Sponsor
Govt Nizamia Tibbi College
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

•Patients clinically diagnosed with Alcoholic Hepatitis.

•Patients of both genders with age range between 20-60 years.

•Patient should be off from any other therapy for the same ailment 1 week prior to his/her enrollment.

•Patients who are willing to give written consent.

Exclusion Criteria

•Patients below 20 years and above 60 years.

•Pregnant and lactating mothers.

•Diabetic patients.

•Patient suffering from other systemic diseases.

•Patients who does not give written consent.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Relief from clinical symptoms and physical signs (Subjective Parameters viz., Anorexia, Nausea,Vomiting,Anxiety,Restlessness, Pain in Abdomen, Low grade Fever, Yellow coloured Urine) along with improvement of biochemical parameters (Objective Parameters viz., Serum γ-glutamyl transferase, Serum Bilirubin, SGOP, SGPT, Alkaline Phosphotase, Hepatomegaly). <br/ ><br> <br/ ><br>An Arbitrary Grading Scale will be adopted for the assessment of subjective parameters. <br/ ><br>Timepoint: Day 1 <br/ ><br>Day 15 <br/ ><br>Day 30 <br/ ><br>Day 45 <br/ ><br>Day 60
Secondary Outcome Measures
NameTimeMethod
Short-Term safety as assessed by change in the safety biochemical parameters (like CBP, ESR, FBS, PPBS, LFT, RFT), and overall compliance to the drug treatment.Timepoint: Day 1 <br/ ><br>Day 60
© Copyright 2025. All Rights Reserved by MedPath